Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

First-in-Human trial tests pill to fight diabetic vision loss

NCT ID NCT04187443

Summary

This early-stage study is testing the safety and initial effects of an oral medication called MS-553 for people with diabetic macular edema, a swelling in the eye that can cause vision loss. Forty-five participants who have not yet received treatment for this condition will take the pill for eight weeks. Researchers will monitor for side effects and check if the drug reduces swelling in the retina and improves vision.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETIC RETINOPATHY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Shanghai General Hospital

    RECRUITING

    Shanghai, 200080, China

    Contact

    Contact

  • The Second Xiangya Hospital of Central South University

    RECRUITING

    Changsha, Hunan, China

  • West China Hospital of Sichuan University

    RECRUITING

    Chengdu, Sichuan, China

Conditions

Explore the condition pages connected to this study.